Literature DB >> 22862176

Ovarian cancer stem cells.

A G Zeimet1, D Reimer, S Sopper, M Boesch, A Martowicz, J Roessler, A M Wiedemair, H Rumpold, G Untergasser, N Concin, G Hofstetter, E Muller-Holzner, H Fiegl, C Marth, D Wolf, M Pesta, J Hatina.   

Abstract

Because of its semi-solid character in dissemination and growth, advanced ovarian cancer with its hundreds of peritoneal tumor nodules and plaques appears to be an excellent in vivo model for studying the cancer stem cell hypothesis. The most important obstacle, however, is to adequately define and isolate these tumor-initiating cells endowed with the properties of anoikis-resistance and unlimited self-renewal. Until now, no universal single marker or marker constellation has been found to faithfully isolate (ovarian) cancer stem cells. As these multipotent cells are known to possess highly elaborated efflux systems for cytotoxic agents, these pump systems have been exploited to outline putative stem cells as a side-population (SP) via dye exclusion analysis. Furthermore, the cells in question have been isolated via flow cytometry on the basis of cell surface markers thought to be characteristic for stem cells.In the Vienna variant of the ovarian cancer cell line A2780 a proof-of-principle model with both a stable SP and a stable ALDH1A1+ cell population was established. Double staining clearly revealed that both cell fractions were not identical. Of note, A2780V cells were negative for expression of surface markers CD44 and CD117 (c-kit). When cultured on monolayers of healthy human mesothelial cells, green-fluorescence-protein (GFP)-transfected SP of A2780V exhibited spheroid-formation, whereas non-side-population (NSP) developed a spare monolayer growing over the healthy mesothelium. Furthermore, A2780V SP was found to be partially resistant to platinum. However, this resistance could not be explained by over-expression of the "excision repair cross-complementation group 1" (ERCC1) gene, which is essentially involved in the repair of platinated DNA damage. ERCC1 was, nonetheless, over-expressed in A2780V cells grown as spheres under stem cell-selective conditions as compared to adherent monolayers cultured under differentiating conditions. The same was true for the primary ovarian cancer cells B-57.In summary our investigations indicate that even in multi-passaged cancer cell lines hierarchic government of growth and differentiation is conserved and that the key cancer stem cell population may be composed of small overlapping cell fractions defined by various arbitrary markers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22862176     DOI: 10.4149/neo_2012_094

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  20 in total

1.  Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.

Authors:  Xiaoqian Yang; Jacson Shen; Yan Gao; Yong Feng; Yichun Guan; Zhan Zhang; Henry Mankin; Francis J Hornicek; Zhenfeng Duan
Journal:  Int J Cancer       Date:  2015-05-05       Impact factor: 7.396

2.  Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.

Authors:  Maximilian Boesch; Alain G Zeimet; Holger Rumpold; Guenther Gastl; Sieghart Sopper; Dominik Wolf
Journal:  Stem Cells Transl Med       Date:  2015-07-01       Impact factor: 6.940

3.  Cripto-1 expression and its prognostic value in human bladder cancer patients.

Authors:  Bingbing Wei; Wei Jin; Jun Ruan; Zhuoqun Xu; You Zhou; Jiabei Liang; Huan Cheng; Ke Jin; Xing Huang; Peng Lu; Qiang Hu
Journal:  Tumour Biol       Date:  2014-10-19

4.  The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles.

Authors:  Yi Mi; Yuqin Huang; Jie Deng
Journal:  Oncol Lett       Date:  2018-03-01       Impact factor: 2.967

Review 5.  Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche.

Authors:  Maximilian Boesch; Sieghart Sopper; Alain G Zeimet; Daniel Reimer; Guenther Gastl; Burkhard Ludewig; Dominik Wolf
Journal:  Biochim Biophys Acta       Date:  2016-10-15

Review 6.  Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research.

Authors:  Nuzhat Ahmed; Kaye L Stenvers
Journal:  Front Oncol       Date:  2013-09-25       Impact factor: 6.244

Review 7.  Ovarian cancer stem cells: a new target for cancer therapy.

Authors:  Qinglei Zhan; Chunmei Wang; Saiming Ngai
Journal:  Biomed Res Int       Date:  2013-01-30       Impact factor: 3.411

Review 8.  Culture models to define key mediators of cancer matrix remodeling.

Authors:  Emily Suzanne Fuller; Viive Maarika Howell
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

9.  Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer.

Authors:  Meghan L Verschoor; Gurmit Singh
Journal:  Mol Cancer       Date:  2013-11-15       Impact factor: 27.401

10.  The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics.

Authors:  Maximilian Boesch; Alain G Zeimet; Daniel Reimer; Stefan Schmidt; Guenther Gastl; Walther Parson; Franziska Spoeck; Jiri Hatina; Dominik Wolf; Sieghart Sopper
Journal:  Oncotarget       Date:  2014-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.